Pricing Log in Create free account
Friday 6 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

118.74 0.73 +0.62%
Market cap
$24.1B
P/E
56.3×
Fwd P/E
55.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Incyte Corporation 8-K filed Mar 6, 2026

Period ended Feb 27, 2026 · Filed · accepted 5:03 PM ET · Document on sec.gov · Filing index

8.01 Other events

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov